Certara stock hits 52-week low at 6.44 USD
Certara Inc. stock has fallen to a new 52-week low of $6.44 USD, marking a significant 53.53% decrease over the past year despite being considered undervalued by InvestingPro analysts. The company's financial health score remains "GOOD," and it recently appointed Jon Resnick as CEO, leading to varied analyst adjustments, including an upgrade from Leerink Partners and a new Buy rating from Rothschild Redburn. Investors are awaiting upcoming earnings and strategies to navigate the current market challenges and recover.
Behavioral Patterns of CERT and Institutional Flows
This article analyzes behavioral patterns and institutional flows for Certara Inc. (NASDAQ: CERT), identifying weak sentiment across all time horizons and supporting a short bias. It provides three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss parameters, along with a multi-timeframe signal analysis. The analysis concludes with elevated downside risk due to a lack of long-term support signals.
Analyst sentiment on Certara (CERT) remains moderately bullish despite sector volatility
Analyst sentiment regarding Certara (CERT) is moderately bullish, despite ongoing volatility in the healthcare sector. CERT has received a consensus rating of "Hold" based on seven analyst ratings. The average price target of $17.57 suggests a potential upside of 11.75% from its last closing price.
Certara, Inc.'s (NASDAQ:CERT) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/S Ratio
Despite a recent 26% share price dip, Certara, Inc. (NASDAQ:CERT) maintains a P/S ratio of 2.7x, which is higher than nearly half of its industry peers in the Healthcare Services sector, raising concerns among shareholders. The company's revenue growth of 11% over the last year and 28% over three years is moderate, but anticipated future growth of 7.1% annually over the next three years is significantly lower than the industry forecast of 13%. This suggests that the high P/S ratio might be unwarranted given the less favorable growth outlook.
Certara, Inc. (NASDAQ:CERT) Receives Consensus Rating of "Moderate Buy" from Brokerages
Certara, Inc. (NASDAQ:CERT) has received a consensus "Moderate Buy" rating from fifteen brokerages, with an average 1-year target price of $12.8182. Several firms recently adjusted their price targets and ratings on the stock, while institutional investors have actively traded Certara shares. The company, which specializes in biosimulation software and services, saw its stock open at $6.93 and has a market capitalization of $1.10 billion.
Analyst sentiment on Certara (CERT) remains moderately bullish despite sector volatility
The article discusses the moderately bullish sentiment surrounding Certara (CERT) among analysts, despite recent volatility in the sector. It suggests that analysts generally maintain a positive outlook on the company's prospects.
Certara stock hits 52-week low at 6.96 USD By Investing.com
Certara Inc. stock has hit a 52-week low of $6.96, representing a 48.79% decline over the past year. Despite this downturn and an oversold RSI, InvestingPro analysis indicates the company has "GOOD" financial health and may be undervalued based on its low P/E ratio relative to near-term earnings growth. Recent leadership changes and positive analyst ratings for its biosimulation technology suggest potential for future recovery.
Analysts Estimate Certara, Inc. (CERT) to Report a Decline in Earnings: What to Look Out for
This article forecasts that Certara, Inc. (CERT) is expected to report a decline in earnings per share for its upcoming report. The consensus EPS estimate is $0.09, representing a year-over-year decrease of 25%, despite revenue expectations of $89.04 million, a 9.3% increase. Investors will be keen to see if Certara can surpass these estimates and provide strong guidance for future growth.
Certara, Inc. (CERT) Investor Outlook: Exploring A Promising 72.59% Potential Upside
Certara, Inc. (NASDAQ: CERT) shows a promising 72.59% potential upside, with analysts issuing eight buy and six hold ratings and a target price of $12.38. The company is a leader in biosimulation for drug discovery, reporting 10.30% revenue growth and positive EPS despite its current stock price being at the lower end of its 52-week range. Technical analysis suggests it is oversold, indicating a potential entry point for long-term investors focused on capital appreciation in the healthcare technology sector.
Certara stock hits 52-week low at 6.96 USD By Investing.com
Certara Inc. stock has hit a 52-week low of $6.96, representing a 48.79% decline over the past year. Despite the downturn and oversold RSI, InvestingPro data suggests the company has "GOOD" financial health and may be undervalued, trading at a low P/E ratio relative to near-term earnings growth. Recent leadership changes and analyst ratings from Stephens, Leerink Partners, and Rothschild Redburn indicate ongoing market attention and potential for future growth.
Analyst sentiment on Certara (CERT) remains moderately bullish despite sector volatility
This article analyzes analyst sentiment for Certara (CERT), observing a moderately bullish outlook despite recent sector volatility. It likely delves into the reasons behind this sentiment, possibly discussing Certara's financial performance, market position, or future prospects. The report aims to provide insights into how financial experts view the company's potential.
Analyst Sentiment on Certara (CERT) Remains Moderately Bullish Despite Sector Volatility
Despite sector volatility, 60% of analysts remain bullish on Certara (CERT) as of February 5, 2026, with a consensus price target of $12.00, implying a 57.70% upside. KeyBanc reiterated an 'Overweight' rating while reducing its price target, citing fundamental momentum. Leerink upgraded Certara to 'Outperform,' highlighting its leadership in biosimulation and viewing a recent selloff as an overreaction, expecting improved market dynamics to accelerate growth.
Certara stock hits 52-week low at 6.96 USD By Investing.com
Certara Inc. (CERT) stock has reached a 52-week low of $6.96, representing a 48.79% decline over the past year. Despite its stock being in oversold territory and a significant drop over the last six months, InvestingPro analysis indicates the company has a "GOOD" financial health score and may be undervalued based on its low P/E ratio relative to near-term earnings growth. This comes amidst a leadership change with Jon Resnick announced as the new CEO and varying analyst ratings from Stephens, Leerink Partners, and Rothschild Redburn.
Certara stock hits 52-week low at 6.96 USD
Certara Inc. (CERT) stock hit a new 52-week low of $6.96, marking a 48.79% decline over the past year and a 34.46% drop in the last six months, with its RSI indicating oversold conditions. Despite these challenges, InvestingPro analysis suggests the company has "GOOD" financial health and may be undervalued given its low P/E ratio relative to near-term earnings growth. This comes amidst recent leadership changes, with Jon Resnick named the new CEO, and varied analyst ratings from Stephens, Leerink Partners, and Rothschild Redburn, all recognizing Certara's leadership in biosimulation.
CERT: Biosimulation Expansion And New CEO Hire Will Support Shares
Certara's average price target has been trimmed to around $12, reflecting caution about competition and regulatory pressure, yet maintaining confidence in its biosimulation leadership and expansion into early-stage drug development. The company recently announced Jon Resnick as its new CEO, effective January 1, 2026, a move that analysts believe, along with improved biopharma spending, could support future growth despite some execution risks. Valuation metrics show a stable fair value, with slight adjustments in discount rate and future P/E.
Certara (NASDAQ:CERT) Raised to Buy at Wall Street Zen
Wall Street Zen has upgraded Certara (NASDAQ:CERT) from a "hold" to a "buy" rating, contributing to an overall "Moderate Buy" consensus among analysts with a target price of $12.82. Despite a high P/E ratio of 103 and trading near its 1-year low, Certara recently surpassed quarterly EPS estimates. Institutional investors hold nearly 74% of the shares, showing significant confidence in the biosimulation software and services company.
(CERT) Movement Within Algorithmic Entry Frameworks
This article analyzes Certara Inc. (NASDAQ: CERT) using AI models to suggest trading strategies. It identifies weak sentiment across all time horizons, supporting a short bias for the stock. Three distinct institutional trading strategies—position trading, momentum breakout, and risk hedging—are provided based on AI-generated signals and risk parameters.
Certara stock hits 52-week low at 8.02 USD
Certara Inc.'s stock reached a new 52-week low of $8.02, plummeting 14.26% in the past week, with a 1-year total return of -40.63%. Despite this, the company maintains a "GOOD" financial health score, and analysts suggest a 44% upside potential, with some upgrading its stock rating. Recent developments include a new CEO appointment and slightly exceeding Q3 2025 earnings expectations.
Certara's (NASDAQ:CERT) Returns On Capital Not Reflecting Well On The Business
Certara's Return On Capital Employed (ROCE) has declined over the last five years to 2.2%, underperforming the Healthcare Services industry average. While capital employed and revenue have increased, suggesting a focus on growth, this has come at the expense of short-term returns. The article suggests that if these investments are successful, long-term stock performance could improve, encouraging astute investors to look further into the stock despite a significant stock price drop.
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter
This article identifies three healthcare stocks—Zai Lab Ltd (ZLAB), Vivos Therapeutics Inc (VVOS), and Certara Inc (CERT)—that are currently oversold, presenting potential buying opportunities. The analysis uses the Relative Strength Index (RSI) below 30 as an indicator for undervaluation. Each stock's recent performance, key company news, and RSI value are discussed, suggesting they could offer significant gains.
Certara stock hits 52-week low at 8.02 USD By Investing.com
Certara Inc.'s stock has reached a new 52-week low of $8.02, representing a 40.63% decline over the past year. Despite this downturn, the company maintains a "GOOD" financial health score and analysts see a 44% upside potential, with several firms maintaining or upgrading their ratings. Recent developments include a new CEO appointment and better-than-expected Q3 2025 earnings.
Certara (NASDAQ:CERT) Hits New 12-Month Low - What's Next?
Certara (NASDAQ:CERT) shares hit a new 52-week low of $7.90 on Tuesday, despite institutional ownership of approximately 74%. Analysts have lowered price targets though the consensus remains a "Moderate Buy" with an average target of $12.58. The company previously exceeded quarterly EPS estimates and set FY2025 guidance, yet trades at a high P/E ratio of 110.7.
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter
This article identifies three oversold healthcare stocks—Zai Lab Ltd (ZLAB), Vivos Therapeutics Inc (VVOS), and Certara Inc (CERT)—that could offer significant gains this quarter. These companies have Relative Strength Index (RSI) values near or below 30, indicating they may be undervalued. The report provides recent company updates, stock performance specifics, and RSI values for each.
Tejara Capital Ltd Purchases 132,927 Shares of Certara, Inc. $CERT
Tejara Capital Ltd significantly increased its stake in Certara, Inc. (NASDAQ:CERT) by 94.9% in the third quarter, purchasing 132,927 additional shares. The firm now holds 273,052 shares of Certara, valued at approximately $3.34 million, making it their 19th largest position. Certara, with a market cap of $1.40 billion and a P/E ratio of 125.57, recently beat its Q3 EPS estimates and received a "Moderate Buy" rating from analysts with an average target price of $12.58.
Certara, Inc.'s (NASDAQ:CERT) Share Price Not Quite Adding Up
Certara, Inc. (NASDAQ:CERT) exhibits a high price-to-sales (P/S) ratio of 3.5x, which is considerably above the industry average for Healthcare Services companies in the United States. Despite recent revenue growth, analysts project Certara's future revenue growth to be slower than the industry average. This disparity suggests that the current high P/S ratio might not be justified and could lead to future share price correction.
A Look At Certara (CERT) Valuation After Weaker Q4 Bookings And Guidance Trim Under New CEO
Certara's (CERT) valuation is under scrutiny following weaker-than-expected Q4 2025 service bookings and a modest guidance trim, despite a 6.21% one-month share price return. While Certara is seen by some narratives as 24% undervalued at $9.40, its high P/E ratio of 137.6x compared to the industry average of 31.1x raises concerns about its potential for future growth. The company's new AI-enabled platform is expected to drive recurring revenue, but softer bookings and biopharma budgets pose risks to its optimistic valuation.
Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025
Certara, Inc. (Nasdaq: CERT) announced that it will release its fourth quarter and full year 2025 financial results before market open on Thursday, February 26, 2026. The company will host a conference call at 8:30 AM ET to discuss these results, and investors are encouraged to register online in advance to participate. A webcast of the event will also be available on Certara's investor relations website.
Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025
Certara, Inc. announced it will release its financial results for the fourth quarter and full year of 2025 before market open on February 26th, 2026. The company will host a conference call at 8:30 AM ET to discuss these results, with a live and archived webcast available on their investor relations website. Investors are encouraged to register online in advance to listen to the call.
Will Certara’s Softer Bookings and New Strategy Redefine Its Competitive Edge (CERT)?
Certara, Inc. (CERT) underperformed due to weaker-than-expected service bookings and a slight reduction in guidance, as reported by Meridian Growth Fund. The company is undergoing a transformation under a new CEO, focusing on commercial execution and potential divestiture of non-core assets, even as its biosimulation tools remain critical for FDA drug approvals. Investors are weighing the near-term risks associated with service pipeline slowdowns and the transition period against the long-term potential of Certara's core software and platforms.
Will Certara’s Softer Bookings and New Strategy Redefine Its Competitive Edge (CERT)?
Certara's recent softer service bookings and lowered guidance, as reported by Meridian Growth Fund, highlight a near-term challenge. The company is undergoing a transformation under a new CEO, focusing on commercial execution and potential divestitures, while its biosimulation tools continue to be crucial for FDA drug approvals. This shift places increased emphasis on the new leadership's ability to drive growth and streamline operations amidst varying investor fair value estimates.
Lower-Than-Expected Service Bookings Impacted Certara (CERT) in Q4
Meridian Growth Fund's Q4 2025 investor letter highlighted Certara, Inc. (NASDAQ:CERT) as a leading relative detractor due to weaker-than-expected service bookings, which led the company to slightly lower its guidance. Despite this, the fund believes Certara is positioned for transformation into a more focused, pure-play growth company under its new CEO, who is adopting a commercially focused strategy. Certara's technology, involving biosimulation for drug development, is already widely used in FDA-approved drugs.
Lower-Than-Expected Service Bookings Impacted Certara (CERT) in Q4
Meridian Growth Fund's Q4 2025 investor letter noted that Certara, Inc. (NASDAQ: CERT) was a leading detractor in the quarter due to weaker-than-expected service bookings, which led to a lowered guidance. Despite this, the fund sees potential for Certara to transform into a more focused growth company under a new CEO with a commercially focused strategy and the possible divestiture of a non-core business segment. The firm, however, suggests other AI stocks might offer greater upside and less risk than Certara.
How (CERT) Movements Inform Risk Allocation Models
This article analyzes Certara Inc. (NASDAQ: CERT) using AI models, identifying a strong near and mid-term sentiment despite a weak long-term outlook. It details specific institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The analysis highlights an exceptional risk-reward setup targeting a 17.7% gain versus 0.3% risk.
Sector Gamma AS Acquires New Stake in Certara, Inc. $CERT
Sector Gamma AS has acquired a new stake of 230,565 shares in Certara, Inc. (NASDAQ:CERT) during Q3, valued at approximately $2.82 million. This purchase contributes to institutional investors collectively owning about 73.96% of the company. Certara, a biosimulation software and services company, holds a consensus "Moderate Buy" rating from analysts with an average target price of $12.58, following a Q3 earnings beat and FY2025 EPS guidance of $0.45-$0.47.
Certara Inc EXPOSED: The Quiet Pharma Tech Power Move Wall Street Is Sleeping On
The article highlights Certara Inc (CERT) as an under-the-radar pharma tech company that provides essential software and services for drug development, clinical trial design, and regulatory processes. It emphasizes Certara's role in "model-informed drug development," enabling faster and more cost-effective drug approvals. While not a mainstream trending stock, its specialized services make it a critical player within the biopharma industry, appealing to investors looking for "picks-and-shovels" businesses in the pharmaceutical gold rush.
Certara Inc EXPOSED: The Quiet Pharma Tech Power Move Wall Street Is Sleeping On
Certara Inc (CERT) is a pharma tech company that provides software and services for model-informed drug development, regulatory support, and market access. While not a trendy social media stock, it plays a crucial role behind the scenes by helping pharmaceutical companies design clinical trials, model drug effects, and navigate regulatory processes more efficiently. The article suggests Certara is an "infrastructure of pharma" play, offering stability and strategic importance rather than quick, volatile gains, and is worth watching for investors interested in deep software solutions within the life sciences.
Certara, Inc. (NASDAQ:CERT) Given Consensus Rating of "Moderate Buy" by Analysts
Certara, Inc. (NASDAQ:CERT) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $12.58. The company recently reported Q3 earnings per share of $0.14 and revenue of $104.62 million, exceeding analyst estimates, and provided FY2025 guidance of $0.450–0.470 EPS. Institutional investors have notably increased their holdings in Certara, with 73.96% of the stock currently owned by institutions and hedge funds.
Trading Systems Reacting to (CERT) Volatility
This article analyzes Certara Inc. (NASDAQ: CERT) using AI models, highlighting a near-term weak sentiment that could test mid-term strength within a broader long-term weak bias. It discusses support and resistance levels, identifying an exceptional risk-reward setup targeting an 18.0% gain. The piece also presents three distinct institutional trading strategies for different risk profiles.
Certara, Inc. (CERT) Stock Analysis: A Healthcare Innovator With 31.79% Potential Upside
Certara, Inc. (CERT) is highlighted as a healthcare innovator specializing in biosimulation and model-informed drug development, with a potential upside of 31.79% according to analyst targets. Despite its current stock price being at the lower end of its 52-week range, the company shows strong revenue growth and a robust free cash flow, prioritizing reinvestment over dividends. Investors are advised to consider its technical indicators and market dynamics while noting its significant growth potential within the healthcare technology sector.
Does Leerink’s Upgrade of Certara (CERT) Reveal a Deeper Edge in Biosimulation-Driven Drug Development?
Leerink Partners recently upgraded Certara (CERT) to an "Outperform" rating, indicating renewed confidence in its biosimulation services. This upgrade supports the long-term thesis that biosimulation will become central to drug R&D, with Certara's updated 2025 revenue outlook of US$415-US$420 million reinforcing adoption expectations. The key challenge for Certara is balancing expanding regulatory acceptance and new AI products against potential cyclical pressures on pharma R&D budgets to justify its premium valuation.
Leerink Partners upgrades Certara stock rating to Outperform
Leerink Partners has upgraded Certara Inc. (NASDAQ:CERT) from Market Perform to Outperform, maintaining a price target of $13.00, suggesting a potential 44% upside. The upgrade is based on Certara's leadership in biosimulation, strong revenue growth, and an improving market despite recent underperformance due to Q3 services bookings and a CEO transition. InvestingPro analysis further supports the stock's valuation, highlighting its low P/E ratio relative to near-term earnings growth and strong free cash flow.
CERT: Keybanc Maintains Overweight Rating, Lowers Price Target t
Keybanc has reiterated its "Overweight" rating for Certara (CERT) but reduced its price target from $13.00 to $12.00, a 7.69% decrease. This adjustment follows several other analyst updates in late 2025 and early 2026, with a consensus average price target of $12.38 among 12 analysts. Certara accelerates drug discovery and development through biosimulation software and technology.
Strong week for Certara (NASDAQ:CERT) shareholders doesn't alleviate pain of five-year loss
Certara, Inc. (NASDAQ:CERT) shareholders have experienced a significant 72% loss over the past five years, with a further 27% drop in the last 90 days, despite a positive turn in the most recent week. While the company's revenue grew by 11% annually over five years, its minimal earnings and stock underperformance suggest that revenue growth alone hasn't translated into shareholder value. Insiders have recently bought shares, which could be a positive sign, but external factors and overall market trends often influence stock performance.
Assessing Certara (CERT) Valuation After Leerink Partners Upgrade To Outperform
Leerink Partners recently upgraded Certara (CERT) to an Outperform rating, drawing attention to its valuation. The company, trading at US$9.49, shows improved revenue and net income growth despite weaker multi-year returns. While a narrative suggests Certara is 24.3% undervalued with a fair value of $12.54 due to its AI-enabled MIDD platform and CertaraIQ QSP software, another view indicates it's expensive at 139x earnings compared to peers.
Leerink Partners Upgrades Certara (CERT)
Leerink Partners upgraded Certara (CERT) from Market Perform to Outperform on January 6, 2026. Analysts project an average one-year price target of $12.79/share, indicating a 33.95% upside from its last closing price. The company shows positive fund sentiment with increased institutional ownership and a bullish put/call ratio.
Leerink Partners upgrades Certara stock rating to Outperform By Investing.com
Leerink Partners upgraded Certara Inc. (NASDAQ:CERT) from Market Perform to Outperform, setting a price target of $13.00, indicating a potential 44% upside. The upgrade is based on Certara's market leadership in biosimulation, solid revenue growth, and an improving market outlook, despite recent underperformance due to Q3 2025 services bookings and a CEO transition. InvestingPro analysis also supports the view that Certara is trading at a low P/E ratio relative to near-term earnings growth.
Leerink Upgrades Certara to Outperform From Market Perform, Price Target is $13
Leerink has upgraded Certara (NASDAQ: CERT) from Market Perform to Outperform, setting a new price target of $13. This upgrade follows a period where Certara's shares have shown recent gains. The company is actively involved in model-informed drug development, utilizing biosimulation software and services to optimize drug discovery and development processes for biopharmaceutical companies, academic institutions, and regulatory agencies globally.
Certara (NASDAQ:CERT) Upgraded by Leerink Partners to Outperform Rating
Leerink Partners upgraded Certara (NASDAQ:CERT) from "market perform" to "outperform" with a $13 price target, signaling a potential upside of 43.8% from its previous close. While analyst views are mixed, the consensus rating for Certara remains "Moderate Buy" with an average target price of $12.92. The company recently beat quarterly EPS estimates and set its FY2025 guidance at $0.45-$0.47 EPS.
Certara’s Volatility: From a 23% Earnings Plunge to a $3 Million Institutional Vote of Confidence
Certara (Nasdaq:CERT) experienced a significant 23% market valuation drop in late 2025 following a Q3 earnings report that signaled a slowdown in core service bookings and narrowed revenue guidance. Despite this, Kopion Asset Management invested over $3.3 million into the stock, viewing it as a "buy the dip" opportunity. The article discusses Certara's challenges, competitive landscape, broader industry trends, and the road ahead under its new CEO, Jon Resnick, as the company navigates a "mixed operating environment."
How Certara Inc. (CERT) Affects Rotational Strategy Timing
This article analyzes Certara Inc. (NASDAQ: CERT) using AI models to provide trading strategies and risk management insights. It identifies a mid-channel oscillation pattern and a favorable risk-reward setup, with signals pointing to a current neutral sentiment. The analysis includes position trading, momentum breakout, and risk hedging strategies for various time horizons.
